Stockscreener 앱 받기
1.365
3.03%
0.045
전일 마감가:
$1.32
열려 있는:
$1.35
하루 거래량:
398.78K
Relative Volume:
0.80
시가총액:
$108.62M
수익:
$7.05M
순이익/손실:
$-30.43M
주가수익비율:
-3.6035
EPS:
-0.3788
순현금흐름:
$21.84M
1주 성능:
+14.29%
1개월 성능:
-17.58%
6개월 성능:
-64.02%
1년 성능:
-32.00%
1일 변동 폭
$1.31
$1.40
1주일 범위
$1.10
$1.40
52주 변동 폭
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
PRQR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.37 | 108.62M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.29 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
582.31 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.60 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.54 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-29 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-11 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-02-01 | 개시 | Raymond James | Strong Buy |
| 2021-05-03 | 개시 | Stifel | Buy |
| 2021-03-25 | 재확인 | Citigroup | Buy |
| 2020-11-03 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-03-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-12-19 | 개시 | RBC Capital Mkts | Outperform |
| 2018-11-15 | 개시 | Citigroup | Buy |
| 2018-09-19 | 개시 | Evercore ISI | Outperform |
| 2017-09-26 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-06-20 | 개시 | Chardan Capital Markets | Neutral |
| 2014-10-15 | 개시 | Deutsche Bank | Buy |
| 2014-10-13 | 개시 | H.C. Wainwright | Buy |
모두보기
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
ProQR Therapeutics N.V (PRQR) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Walleye Capital LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Sees Significant Decline in Short Interest - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Affinity Asset Advisors LLC Makes New Investment in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
575,000 Shares in ProQR Therapeutics (NASDAQ:PRQR) Bought by Altium Capital Management LLC - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of “Buy” by Brokerages - Defense World
Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com
Retinitis Pigmentosa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics - Barchart.com
ProQR (PRQR) Strengthens Leadership with New CFO and CMO Appointments | PRQR Stock News - GuruFocus
ProQR Strengthens Leadership with Appointments of CFO and CMO to - GuruFocus
ProQR names new CFO and CMO to bolster RNA editing platform By Investing.com - Investing.com South Africa
ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 34% - simplywall.st
ProQR names new CFO and CMO to bolster RNA editing platform - Investing.com Canada
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth - GlobeNewswire
ProQR strengthens leadership team - The Pharma Letter
ProQR Therapeutics CFO Jurriaan Dekkers Steps Down, Dennis Hom To Succeed; Cristina Lopez Named CMO - Nasdaq
ProQR's Leadership Overhaul: New CFO Raised $4.5B, Led $57B in Deals - Stock Titan
American Century Companies Inc. Invests $237,000 in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Shares Acquired by Prudential Financial Inc. - Defense World
Raymond James Financial Inc. Acquires Shares of 97,928 ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Virtu Financial LLC Buys New Stake in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Chardan Capital Issues Optimistic Forecast for PRQR Earnings - MarketBeat
FY2025 EPS Estimate for ProQR Therapeutics Lifted by Analyst - Defense World
28,903 Shares in ProQR Therapeutics (NASDAQ:PRQR) Acquired by PNC Financial Services Group Inc. - Defense World
Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Price Target at $9.50 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Receives $9.50 Average Target Price from Analysts - The AM Reporter
Privium Fund Management B.V. Sells 646,755 Shares of ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
Platinum Investment Management Ltd. Makes New $4.08 Million Investment in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of “Buy” by Brokerages - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Chardan Capital - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for ProQR Therapeutics (NASDAQ:PRQR) Stock - MarketBeat
H.C. Wainwright raises ProQR stock target to $12, maintains Buy By Investing.com - Investing.com Australia
H.C. Wainwright raises ProQR stock target to $12, maintains Buy - Investing.com India
ProQR Therapeutics (NASDAQ:PRQR) Issues Quarterly Earnings Results - MarketBeat
Chardan Capital Reaffirms Buy Rating for ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Raymond James maintains Strong Buy on ProQR stock, $14 target By Investing.com - Investing.com Australia
Raymond James maintains Strong Buy on ProQR stock, $14 target - Investing.com India
ProQR Therapeutics NV earnings beat, revenue fell short of estimates - Investing.com
ProQR Therapeutics NV earnings beat, revenue fell short of estimates By Investing.com - Investing.com South Africa
Proqr Therapeutics N V (PRQR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.75%
2.22%
자본화:
|
볼륨(24시간):